{"schema_version":"secwatch.filing_event.v1","accession":"0001534969-23-000111","form_type":"8-K","ticker":"SERA","cik":"0001534969","company_name":"SERA PROGNOSTICS, INC.","filed_at":"2023-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.415147+00:00","generated_at":"2026-06-08T09:19:12.909878+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Sera Prognostics Q3 net loss narrows to $7.2M; appoints permanent CEO and CFO","bullets":["Revenue of $42k vs $87k YoY; net loss $7.2M vs $10.7M in Q3 2022.","Operating expenses down to $8.2M from $11.3M; cash of $85M extends runway through most of 2027.","Board approved permanent CEO Zhenya Lindgardt and CFO Austin Aerts.","AVERT trial shows PreTRM test drove 2.5-week gestational age improvement and 18% reduction in severe neonatal morbidity.","New high-low risk predictor product enters next phase of market research; care coordination offering launched."],"urls":{"canonical":"https://secwatch.observer/filing/0001534969-23-000111","json":"https://secwatch.observer/filing/0001534969-23-000111.json","markdown":"https://secwatch.observer/filing/0001534969-23-000111.md","text":"https://secwatch.observer/filing/0001534969-23-000111.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534969/000153496923000111/0001534969-23-000111-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534969/000153496923000111/sera-20231108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T09:19:12.909878+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d4ba942dace1aafa65a8b6c2792900009e19e576","claim":"SERA PROGNOSTICS, INC. reported the third quarter ended September 30, 2023 results: revenue $42,000, net income $7.2 million.","evidence_excerpt":"Third quarter 2023 revenue of $42,000 compared to $87,000 for the same period of 2022. Total operating expenses were $8.2 million, down significantly from $11.3 million for the third quarter of 2022. Research and development expenses for the third quarter of 2023 were $3.5 million compared to $4.2 million for the third quarter of 2022 due primarily to lower clinical study costs. Selling, general and administrative expenses for the third quarter of 2023 were $4.6 million, down significantly from $7.0 million for the third quarter of 2022 due primarily to steps we took prior to year-end 2022 and more recently to streamline commercial operations, better focus our commercial strategy in response to market dynamics and align our administrative costs to match our current level of operations. Net loss for the third quarter of 2023 was $7.2 million compared to $10.7 million for the same quarter a year ago.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534969/000153496923000111/0001534969-23-000111-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Revenue","value":"$42,000"},{"label":"Net income","value":"$7.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}